These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 37480275)

  • 1. Comparative Assessment of Reimbursement Recommendations by NICE and HAS for Oncology New Medicines Indicated for the Treatment of Solid Tumors from 2015 to 2021.
    Trouiller JB; Laramée P
    Med Decis Making; 2023; 43(7-8):961-972. PubMed ID: 37480275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health technology assessment for cancer medicines across the G7 countries and Oceania: an international, cross-sectional study.
    Jenei K; Raymakers AJN; Bayle A; Berger-Thürmel K; Cherla A; Honda K; Jackson CCGA; Karikios D; Trapani D; Berry S; Gyawali B
    Lancet Oncol; 2023 Jun; 24(6):624-635. PubMed ID: 37269843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies.
    Bloem LT; Vreman RA; Peeters NWL; Hoekman J; van der Elst ME; Leufkens HGM; Klungel OH; Goettsch WG; Mantel-Teeuwisse AK
    Clin Transl Sci; 2021 Jul; 14(4):1566-1577. PubMed ID: 33786991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health technology assessment (HTA) in England, France and Germany: what do matched drug pairs tell us about recommendations by national HTA agencies?
    Schaefer R; Hernandez D; Selberg L; Schlander M
    J Comp Eff Res; 2021 Nov; 10(16):1187-1195. PubMed ID: 34583534
    [No Abstract]   [Full Text] [Related]  

  • 5. Appraisals by Health Technology Assessment Agencies of Economic Evaluations Submitted as Part of Reimbursement Dossiers for Oncology Treatments: Evidence from Canada, the UK, and Australia.
    Ball G; Levine MAH; Thabane L; Tarride JE
    Curr Oncol; 2022 Oct; 29(10):7624-7636. PubMed ID: 36290879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparative analysis of two contrasting European approaches for rewarding the value added by drugs for cancer: England versus France.
    Drummond M; de Pouvourville G; Jones E; Haig J; Saba G; Cawston H
    Pharmacoeconomics; 2014 May; 32(5):509-20. PubMed ID: 24599784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The maze of real-world evidence frameworks: from a desert to a jungle! An environmental scan and comparison across regulatory and health technology assessment agencies.
    Sarri G; Hernandez LG
    J Comp Eff Res; 2024 Sep; 13(9):e240061. PubMed ID: 39132748
    [No Abstract]   [Full Text] [Related]  

  • 8. Health Technology Assessment (HTA) Case Studies: Factors Influencing Divergent HTA Reimbursement Recommendations in Australia, Canada, England, and Scotland.
    Allen N; Walker SR; Liberti L; Salek S
    Value Health; 2017 Mar; 20(3):320-328. PubMed ID: 28292476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using Real-World Data in Health Technology Assessment (HTA) Practice: A Comparative Study of Five HTA Agencies.
    Makady A; van Veelen A; Jonsson P; Moseley O; D'Andon A; de Boer A; Hillege H; Klungel O; Goettsch W
    Pharmacoeconomics; 2018 Mar; 36(3):359-368. PubMed ID: 29214389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early access for innovative oncology medicines: a different story in each nation.
    Cowling T; Nayakarathna R; Wills AL; Tankala D; Paul Roc N; Barakat S
    J Med Econ; 2023; 26(1):944-953. PubMed ID: 37466223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval.
    Cherla A; Naci H; Kesselheim AS; Gyawali B; Mossialos E
    JAMA Intern Med; 2021 Apr; 181(4):490-498. PubMed ID: 33616607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncology drug health technology assessment recommendations: Canadian versus UK experiences.
    Chabot I; Rocchi A
    Clinicoecon Outcomes Res; 2014; 6():357-67. PubMed ID: 25075196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical benefit, reimbursement outcomes, and prices of FDA-approved cancer drugs reviewed through Project Orbis in the USA, Canada, England, and Scotland: a retrospective, comparative analysis.
    Jenei K; Gentilini A; Haslam A; Prasad V
    Lancet Oncol; 2024 Aug; 25(8):979-988. PubMed ID: 39004098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world evidence in lung and hematologic oncology health technology appraisals: a review of six assessment agencies.
    Harricharan S; Curran E; Lin HM; Walton L; Gurjar K; Nguyen K; Forsythe A
    Future Oncol; 2023 Mar; 19(8):603-616. PubMed ID: 37083358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing patient access to pharmaceuticals in the UK and US.
    Cohen J; Cairns C; Paquette C; Faden L
    Appl Health Econ Health Policy; 2006; 5(3):177-87. PubMed ID: 17132032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using 5 consecutive years of NICE guidance to describe the characteristics and influencing factors on the economic evaluation of orphan oncology drugs.
    Shengnan D; Zixuan L; Na Z; Weikai Z; Yuanyuan Y; Jiasu L; Ni Y
    Front Public Health; 2022; 10():964040. PubMed ID: 36187695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework.
    Murphy P; Glynn D; Dias S; Hodgson R; Claxton L; Beresford L; Cooper K; Tappenden P; Ennis K; Grosso A; Wright K; Cantrell A; Stevenson M; Palmer S
    Health Technol Assess; 2021 Dec; 25(76):1-228. PubMed ID: 34990339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health Technology Assessment-Informed Decision Making by the Federal Joint Committee/Institute for Quality and Efficiency in Health Care in Germany and the National Institute for Health and Care Excellence in England: The Role of Budget Impact.
    Schaefer R; Hernández D; Bärnighausen T; Kolominsky-Rabas P; Schlander M
    Value Health; 2023 Jul; 26(7):1032-1044. PubMed ID: 36921901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HTA'd in the USA: A Comparison of ICER in the United States with NICE in England and Wales.
    Thokala P; Carlson JJ; Drummond M
    J Manag Care Spec Pharm; 2020 Sep; 26(9):1162-1170. PubMed ID: 32857653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.